Aduro Biotech Reports Fourth Quarter and Full Year 2018 Financial Results
February 27, 2019 at 16:05 PM EST
BERKELEY, Calif., Feb. 27, 2019 (GLOBE NEWSWIRE) -- Aduro Biotech, Inc. (NASDAQ: ADRO) today reported financial results for the fourth quarter and full year ended December 31, 2018.
“2018 was an important year for Aduro as we prioritized our core technologies and determined a go-forward strategy that is committed to maintaining a leadership role in the STING and APRIL pathways and advancing our clinical programs in areas of high unmet medical need,” said Stephen T. Isaacs, chairman, president and chief executive officer of Aduro. “With our strategic focus established and $277.9 million in cash taking us into 2022, we are eager to execute on our clinical development plans for 2019 and beyond.”
Key Accomplishments in Fiscal Year 2018
Cautionary Note on Forward-Looking Statements